Genome Medical
PrivateLast Round
Series D
Sep 1, 2024
Est. Valuation
$39M
Total Funding Raised
$195.34M
Company Overview
Genome Medical operates in Healthcare & Life Sciences and is based in South San Francisco, California. Its latest recorded funding round was a Series D round in September 2024.
Genome Medical is a digital health company that provides telehealth-enabled genetic counseling and genomic medicine services to individuals, healthcare providers, and health systems.
Sector
Healthcare & Life Sciences
Verticals
Telemedicine, Precision Medicine, Clinical Trials, Biotechnology
Business Model
B2B2C
Customer Profile
Services & Consulting, Subscription SaaS, Data as a Service
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Genome Medical Comparables
Compare Genome Medical with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| InformedDNA | 85% | |
| Metis Genetics | 82% | |
| DNAvisit | 81% |
For institutional investors. Book with your work email.
Genome Medical Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series D | Sep 1, 2024 | ||||
| Series C | Aug 30, 2021 | ||||
| Series B Extension | Jul 1, 2020 | ||||
| Series B | Jun 11, 2019 | ||||
| Series A Extension | Jan 5, 2018 | ||||
Series A | May 25, 2017 |
For institutional investors. Book with your work email.
Genome Medical Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| GV | Series C |
| Perceptive Advisors | Series C, Series B Extension, Series B |
| Kaiser Permanente Ventures | Series C, Series B Extension, Series B, Series A Extension |
| Manatt Ventures | Series B, Series B Extension |
| Avestria Ventures | Series C, Series B Extension |
| Dreamers VC | Series C, Series B Extension |
| Amgen Ventures | Series C |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 3, 2025
Recognized as one of the Top 50 in Digital Health.
- Jan 17, 2025
Partnered with Nest Genomics to expand genetic services access.
For institutional investors. Book with your work email.
Genome Medical Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Genome Medical's valuation, stock price, and market status.
Is Genome Medical a public or private company?
Genome Medical is a private company.
What is the current stock price of Genome Medical?
Genome Medical is a private company, so its shares have no public market price. Caplight tracks Genome Medical's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Genome Medical worth (valuation)?
Genome Medical's valuation is estimated at $39.0M based on funding round data.
Can I buy Genome Medical stock?
Genome Medical shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Genome Medical's last funding round?
Genome Medical's most recent funding round was Series D on September 1, 2024.
Who are the main investors in Genome Medical?
Key investors in Genome Medical include Canaan Partners, Casdin Capital, Echo Health Ventures, GE Ventures.
Will Genome Medical IPO soon?
No public IPO plans have been announced for Genome Medical.
How can I track Genome Medical secondary market activity?
Caplight tracks bids, offers, and trades in Genome Medical's shares on secondary markets.